efanesoctocog alfa (BIVV001) — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2027-01-15 in 4mo
ESTIMATED |
READOUT
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Trea
Phase 3 · Hemophilia A |
Bioverativ, a Sanofi company | efanesoctocog alfa (BIVV001) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-10-01
Sponsor-projected date — can change
|